Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyloris Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2025 was €0.07 Mil. It means Hyloris Pharmaceuticals's inventory
declined by €0.07 Mil
from Jun. 2025 to Dec. 2025 .
Hyloris Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2025 was €-0.05 Mil. It means Hyloris Pharmaceuticals's inventory
increased by €0.05 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Hyloris Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2025 was 63.98.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Hyloris Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2025 was 2.85.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hyloris Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.02.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hyloris Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals Change In Inventory Related Terms
Hyloris Pharmaceuticals Change In Inventory Historical Data
* Premium members only.
The historical data trend for Hyloris Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of €-0.05 Mil mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Change In Inventory of €-0.05 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' Change In Inventory too high?
Hyloris Pharmaceuticals' current Change In Inventory is €-0.05 Mil. Overall, Hyloris Pharmaceuticals has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Change In Inventory compare to VRTX and REGN?
Hyloris Pharmaceuticals' Change In Inventory of €-0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Change In Inventory is €-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Hyloris Pharmaceuticals (LTS:0AB6) has a current Change In Inventory of €-0.05 Mil. The stock's GF Value™ is €10.00, compared to a current price of €4.55 — trading 54.5% below its estimated fair value. The current Change In Inventory is €-0.05 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Change In Inventory is €-0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.55 is trading 54.5% below its estimated GF Value™ of €10.00.
Key valuation signals for LTS:0AB6:
Change In Inventory: €-0.05 Mil
GF Value™: €10.00 vs. price of €4.55 (54.5% below fair value)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
65GF Score
Get the complete analysis for LTS:0AB6
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
